https://www.bio.org/events/bio-international-convention/start-stadium-2023
May 15, 2023
https://resiconference.com/pitch-challenge/
April 28, 2023
September 22, 2022
In an aging society with a declining birthrate, it is important not only to extend healthy life expectancy, but also to maintain the number of healthy children. We try to solve the problems of both pediatric and aging diseases.
FELIQS【fíːlɪks】 is a preclinical-stage start-up company established based on the robust science from molecular pathobiology, department of pharmaceutical science, Kyushu university.
Ferroptosis is a new type of cell death reported in 2012(Cell. 2012 May 25;149(5):1060-72.), and it is caused by the accumulation of oxidized lipids. In recent years, it has been reported to be associated with many diseases such as cancer, ischemia-reperfusion injury, and neurodegenerative diseases, and is being investigated as a new drug target. We have established a unique drug discovery platform targeting ferrotosis/oxidized lipids, and are now conducting preclinical research toward the clinical trial to create new medicine for unmet medical needs in ophthalmology space.
Name
FELIQS CORPORATION
Code | Target Indications |
administration Route |
Regulatory Pathway |
Preclinical | Clinical | ||
---|---|---|---|---|---|---|---|
Discovery / Research | Lead optimization | IND enabling | Phase I/II | ||||
FLQ-101 | Retinopathy of Prematurity (ROP) | Intravenous | 505(b)(2) | ||||
FLQ-104 | Geographic Atrophy / wet AMD | Oral | 505(b)(1) |
Feel free to write down your inquiry in the following form.